Acumen Pharmaceuticals' sabirnetug misses primary endpoint in Phase 2 Alzheimer's trial
ABOS•Acumen Pharmaceuticals said its Phase 2 ALTITUDE-AD trial of sabirnetug failed its primary endpoint, with neither dose showing meaningful improvement over placebo. The company will stop development, including the open-label extension, and plans cash conservation measures while evaluating strategic options.
1. Trial results
Acumen Pharmaceuticals said its Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease failed its primary endpoint. Neither dose showed meaningful improvement in cognitive or functional decline compared with placebo, and key secondary efficacy endpoints also failed.
2. Development plans
The company will cease sabirnetug development, including the trial’s open-label extension. It plans cash conservation measures while evaluating strategic options, including for its Enhanced Brain Delivery program.
